281 related articles for article (PubMed ID: 18816045)
1. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
2. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
3. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening: an application to human topoisomerase II alpha.
Christmann-Franck S; Bertrand HO; Goupil-Lamy A; der Garabedian PA; Mauffret O; Hoffmann R; Fermandjian S
J Med Chem; 2004 Dec; 47(27):6840-53. PubMed ID: 15615533
[TBL] [Abstract][Full Text] [Related]
6. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
7. Self-association and DNA binding properties of the human topoisomerase IIA alpha2HTH module.
Morant-Lhomel A; René B; Zargarian L; Troalen F; Mauffret O; Fermandjian S
Biochimie; 2006; 88(3-4):253-63. PubMed ID: 16213649
[TBL] [Abstract][Full Text] [Related]
8. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
9. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
11. The topopyrones poison human DNA topoisomerases I and II.
Khan QA; Elban MA; Hecht SM
J Am Chem Soc; 2008 Oct; 130(39):12888-9. PubMed ID: 18774813
[TBL] [Abstract][Full Text] [Related]
12. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
[TBL] [Abstract][Full Text] [Related]
13. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
14. In silico studies with human DNA topoisomerase-II alpha to unravel the mechanism of in vitro genotoxicity of benzene and its metabolites.
Pandey AK; Gurbani D; Bajpayee M; Parmar D; Ajmani S; Dhawan A
Mutat Res; 2009 Feb; 661(1-2):57-70. PubMed ID: 19059273
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors.
Hueso-Falcón I; Amesty Á; Anaissi-Afonso L; Lorenzo-Castrillejo I; Machín F; Estévez-Braun A
Bioorg Med Chem Lett; 2017 Feb; 27(3):484-489. PubMed ID: 28040393
[TBL] [Abstract][Full Text] [Related]
16. Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.
Jonstrup AT; Thomsen T; Wang Y; Knudsen BR; Koch J; Andersen AH
Nucleic Acids Res; 2008 Nov; 36(19):6165-74. PubMed ID: 18824478
[TBL] [Abstract][Full Text] [Related]
17. First synthesis and anticancer activity of novel naphthoquinone amides.
Pradidphol N; Kongkathip N; Sittikul P; Boonyalai N; Kongkathip B
Eur J Med Chem; 2012 Mar; 49():253-70. PubMed ID: 22280818
[TBL] [Abstract][Full Text] [Related]
18. A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.
Kondapi AK; Satyanarayana N; Saikrishna AD
Arch Biochem Biophys; 2006 Jun; 450(2):123-32. PubMed ID: 16712776
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and molecular docking studies of naphthoquinone derivatives on the ATPase domain of human topoisomerase II.
Boonyalai N; Sittikul P; Pradidphol N; Kongkathip N
Biomed Pharmacother; 2013 Mar; 67(2):122-8. PubMed ID: 23089478
[TBL] [Abstract][Full Text] [Related]
20. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
